Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A-Reference-Cited by-同舟云学术

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A

Published:2014-11-13 Issue:20 Volume:124 Page:3165-3171
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Muto Atsushi¹,Yoshihashi Kazutaka¹,Takeda Minako¹,Kitazawa Takehisa¹,Soeda Tetsuhiro¹,Igawa Tomoyuki¹,Sampei Zenjiro¹,Kuramochi Taichi¹,Sakamoto Akihisa¹,Haraya Kenta¹,Adachi Kenji¹,Kawabe Yoshiki¹,Nogami Keiji²,Shima Midori²,Hattori Kunihiro¹

Affiliation:

1. Research Division, Chugai Pharmaceutical Co, Ltd, Gotemba, Shizuoka, Japan; and

2. Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan

Abstract

Key Points A long-term acquired hemophilia A model expressing spontaneous joint bleeds and other bleeds was newly established in nonhuman primates. Weekly SC dose of the anti-FIXa/X bispecific antibody ACE910 prevented joint bleeds and other bleeds in the primate hemophilia A model.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/20/3165/1381692/3165.pdf

Reference35 articles.

1. Pharmacotherapy of haemophilia A.;Gringeri;Expert Opin Biol Ther,2011

2. Modern haemophilia care.;Berntorp;Lancet,2012

3. Blood-induced joint damage in hemophilia.;Roosendaal;Semin Thromb Hemost,2003

4. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.;Manco-Johnson;N Engl J Med,2007

5. Prophylaxis in bleeding disorders.;Oldenburg;Thromb Res,2011

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy;Thrombosis and Haemostasis;2024-08-12

2. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents;Seminars in Thrombosis and Hemostasis;2024-06-12

3. Inhibitor eradication and treatment for acquired hemophilia A;Expert Review of Hematology;2024-05-09

4. Design and engineering of bispecific antibodies: insights and practical considerations;Frontiers in Bioengineering and Biotechnology;2024-01-25

5. The role of emicizumab in acquired hemophilia A;Hematology;2023-12-08